The available data suggested that brivaracetam can be a safe treatment option in patients with status epilepticus. No serious adverse effects were reported. The time from brivaracetam administration to status epilepticus cessation ranged from 15 min to 94 h. In case series, the proportion of patients achieving clinical status epilepticus cessation when brivaracetam was administered as the last drug varied from 27 to 50% in case reports, all patients had status epilepticus cessation. The initial brivaracetam dose ranged from 50 to 400 mg. The time from status epilepticus onset to brivaracetam administration ranged from 0.5 h to 105 days. The number of drugs used prior to brivaracetam to treat status epilepticus ranged from 1 to 8. The type and etiology of status epilepticus varied across studies. Seven studies were included (37 patients aged 22–85 years 21 were female). Searches were conducted on 3 December, 2018. We systematically searched MEDLINE, EMBASE, Google Scholar,, and conference proceedings to identify studies evaluating intravenous brivaracetam as treatment for status epilepticus of any type in patients of any age. The objective of our study was to review the evidence about the clinical efficacy and tolerability of intravenous brivaracetam in the treatment of status epilepticus.

These properties make brivaracetam potentially an ideal compound in the emergency setting. Brivaracetam is a high-affinity synaptic vesicle glycoprotein 2A ligand with high brain permeability and rapid onset of action.

Eset trial status epilepticus